The evaluation of a nucleoprotein ELISA for the detection of equine influenza antibodies and the differentiation of infected from vaccinated horses (DIVA)

Influenza and Other Respiratory Viruses

Pamela Galvin¹  Sarah Gildea¹  Sean Arkins³  Cathal Walsh² 

[1] The Irish Equine Centre, Johnstown, Naas, Co. Kildare, Ireland;Department of Statistics, Trinity College, Dublin, Ireland;Department of Life Sciences, University of Limerick, Limerick, Ireland

关键词: Antibody;    DIVA;    ELISA;    equine;    influenza;    nucleoprotein;   

DOI  :  10.1111/irv.12195

来源: Wiley

【 摘 要 】

Abstract

Background

Antibodies against equine influenza virus (EIV) are traditionally quantified by haemagglutination inhibition (HI) or single radial haemolysis (SRH).

Objectives

To evaluate an ELISA for the detection of antibodies against influenza nucleoprotein in the diagnosis and surveillance of equine influenza (EI).

Methods

The ELISA was compared with the SRH and HI tests. Serial serum samples from 203 naturally and 14 experimentally infected horses, from 60 weanlings following primary vaccination with five different vaccines (two whole inactivated vaccines, two ISCOM-based subunit vaccines and a recombinant canarypox virus vaccine) and from 44 adult horses following annual booster vaccination with six different vaccines were analysed.

Results

Fewer seroconversions were detected in clinical samples by ELISA than by SRH or HI but ELISA was more sensitive than SRH in naïve foals post-experimental infection. The ELISA did not detect the antibody response to vaccination with the recombinant canarypox virus vaccine confirming the usefulness of the combination of this kit and vaccine to differentiate between naturally infected and vaccinated horses, that is, DIVA. No DIVA capacity was evident with the other vaccines.

Conclusion

The results suggest that this ELISA is a useful supplementary test for the diagnosis of EI although less sensitive than HI or SRH. It is an appropriate test for EI surveillance in a naïve population and may be combined with the recombinant canarypox virus vaccine but not with other commercially available subunit vaccines, in a DIVA strategy.

【 授权许可】

Unknown   
© 2013 Blackwell Publishing Ltd